压力支持通气联合叹气在急性低氧性呼吸衰竭患者中的试点随机对照试验:PROTECTION研究方案
PROTECTION是一项国际随机对照试点试验,拟在23个ICU纳入急性低氧性呼吸衰竭患者,比较压力支持通气(PSV)联合叹气(sigh)与标准PSV的可行性。主要终点为28天内辅助通气失败率(联合组15% vs 标准组22%),每组计划129例。若阳性,将为后续更大规模试验验证28天生存和免通气天数奠定基础。
要点
- PSV联合叹气可能优化肺复张、减少异质性和吸气努力,降低肺损伤风险。
- 试验先进行30分钟叹气测试识别早期氧合反应者,再随机分组至拔管、出ICU、死亡或第28天。
- 主要可行性终点为28天内辅助通气失败率,联合组目标15% vs 标准组22%。
核心结论
- PROTECTION试点试验旨在验证在PSV基础上添加叹气治疗急性低氧性呼吸衰竭的可行性。
- 若结果阳性,叹气可能成为标准PSV的有效补充以保护肺并减少辅助通气失败。
- 该试验将为未来更大规模试验验证PSV+叹气对28天生存和免通气天数的影响提供基础。
研究设计与样本
- 国际随机对照试点试验,计划在23个重症监护病房(ICU)开展。
- 纳入插管24小时至7天且接受PSV 4至24小时的急性低氧性呼吸衰竭患者。
- 所有患者先接受30分钟叹气测试以识别早期氧合反应者,随后随机分为PSV组或PSV+叹气组。
- 按80%把握度和5%单侧风险计算,每组需129例患者。
关键数值与推荐
- 叹气实施方式为每分钟一次、持续3秒、压力控制30 cmH2O的呼吸。
- 主要终点为28天内辅助通气失败率,联合组预期15% vs 标准组22%。
- 失败定义为转为控制通气超过24小时、使用挽救治疗或择期拔管后48小时内再插管。
- 随机分组后干预持续至拔管、出ICU、死亡或第28天。
临床怎么用
- 标准化方案将指导通气设置、转回控制通气、挽救治疗、自主呼吸试验、拔管和再插管。
- 临床医生可参考本试点试验评估在PSV中添加叹气的可行性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adding cyclic short sustained inflations (sigh) to assisted ventilation yields optimizes lung recruitment, decreases heterogeneity and reduces inspiratory effort in patients with acute hypoxemic respiratory failure (AHRF). These findings suggest that adding sigh to pressure support ventilation (PSV) might decrease the risk of lung injury, shorten weaning and improve clinical outcomes. Thus, we conceived a pilot trial to test the feasibility of adding sigh to PSV (the PROTECTION study). METHODS: PROTECTION is an international randomized controlled trial that will be conducted in 23 intensive care units (ICUs). Patients with AHRF who have been intubated from 24 h to 7 days and undergoing PSV from 4 to 24 h will be enrolled. All patients will first undergo a 30-min sigh test by adding sigh to clinical PSV for 30 min to identify early oxygenation responders. Then, patients will be randomized to PSV or PSV + sigh until extubation, ICU discharge, death or day 28. Sigh will be delivered as a 3-s pressure control breath delivered once per minute at 30 cmH2O. Standardized protocols will guide ventilation settings, switch back to controlled ventilation, use of rescue treatments, performance of spontaneous breathing trial, extubation and reintubation. The primary endpoint of the study will be to verify the feasibility of PSV + sigh evaluated through reduction of failure to remain on assisted ventilation during the first 28 days in the PSV + sigh group versus standard PSV (15 vs. 22%). Failure will be defined by switch back to controlled ventilation for more than 24 h or use of rescue treatments or reintubation within 48 h from elective extubation. Setting the power to 80% and first-risk order to 5%, the computed size of the trial is 129 patients per arm. DISCUSSION: PROTECTION is a pilot randomized controlled trial testing the feasibility of adding sigh to PSV. If positive, it will provide physicians with an effective addition to standard PSV for lung protection, able to reduce failure of assisted ventilation. PROTECTION will provide the basis for a future larger trial aimed at verifying the impact of PSV + sigh on 28-day survival and ventilator-free days. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03201263 . Registered on 28 June 2017.
引用
- Mauri T, Foti G, Fornari C, et al. Pressure support ventilation + sigh in acute hypoxemic respiratory failure patients: study protocol for a pilot randomized controlled trial, the PROTECTION trial. Trials. 2018. PMID: 30157955. doi:10.1186/s13063-018-2828-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。